DILTIAZEM IN RENAL-ALLOGRAFT RECIPIENTS RECEIVING CYCLOSPORINE
DILTIAZEM IN RENAL-ALLOGRAFT RECIPIENTS RECEIVING CYCLOSPORINE
复制标题
DOI：
10.1097/00007890-199302000-00014
复制
发表时间：
1993-02-01
期刊：
影响因子：
6.2
通讯作者：
MATHEW, TH
中科院分区：
文献类型：
--
作者：
CHRYSOSTOMOU, A;WALKER, RG;MATHEW, TH
在 113 名接受环孢菌素治疗的原发性同种异体肾移植受者中，60 名被随机分配接受不加地尔硫卓的标准治疗 (ND)，53 名接受标准治疗加地尔硫卓 (D)。在 3 至 24 个月的随访期间，ND 和 D 之间的 CsA 血液水平没有差异，但 D 组需要的 CsA 比 ND 组少 35%（在 12 个月时测量）。在截至 24 个月的所有时间间隔内，两组之间的血压、肾功能（通过血清肌酐测量）或移植物丢失数量（ND，4 例丢失；D，3 例丢失）没有差异。两组排斥反应总数无显着差异（ND，89 次；D，71 次）。然而，ND 组排斥反应的严重程度更高，这一点可以通过 OKT3 使用的显着差异来证明（ND，17 个疗程；D，OKT3 8 个疗程，P
Of 113 cyclosporine-treated primary renal allograft recipients, 60 were randomized to receive standard therapy without diltiazem (ND) and 53 received standard therapy plus diltiazem (D). There was no difference in CsA blood levels between ND and D at all intervals between 3 and 24 months follow-up, yet the D group required 35% less CsA than the ND group (measured at 12 months). At all intervals to 24 months there was no difference in blood pressure, renal function (as measured by serum creatinine), or in the number of grafts lost between the 2 groups (ND, 4 lost; D, 3 lost). There was no significant difference in the total number of rejection episodes in the 2 groups (ND, 89 episodes; D, 71 episodes). However, the severity of rejection episodes was greater in the ND group as evidenced by a significant difference in the usage of OKT3 (ND, 17 courses; D, 8 courses of OKT3, P